Dynavax Alternative investors have found plenty of strong bargain opportunities during the Coronavirus Pandemic. Dynavax Technologies Corp. (NASDAQ: DVAX) is a pick that is relevant to the times. The company is most known for its Heplisav hepatitis B vaccine. More recently, it has worked with Medigen Vaccine Biologics to develop a COVID-19 vaccine that is now in Phase 2 clinical trials. Dynavax provides its proprietary adjuvant for the Medigen vaccine. An adjuvant is a vaccine ingredient that helps to create a stronger immune response.

There’s potential in the Dynavax-Medigen vaccine. But, even if it doesn’t come to market, Dynavax is already generating strong growth from Heplisav. In the most recent quarter, Heplisav generated revenue of $11.6 million, up from $10.2 million in the year-ago period. Dynavax now controls 23% of the market for hepatitis vaccines. Its product achieves efficacy in two doses over one month, while competitors take up to six months before immunity is achieved.

Innovative pharmaceutical companies are strong growth options for investors today. This stock was up 130% for the year when the markets closed on Monday. With an average target price of $16.33 and a high-end target price of $20.00, there could be strong gains for investors who buy now.

Key Data:

  • 1 Year Price Growth: 65%
  • YTD Price Growth: 79%
  • 3 Month Price Growth: 14%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.